GNbAC1, an IgG4 mAb currently in stage II clinical trials for safety and pharmacokinetics analysis, neutralize the expression of the envelope protein of Mulitple Sclerosis Retrovirus 132, an endogenous human retrovirus that has been linked with MS. Here, ERVW-1 is linked to myeloid sarcoma.